Skip to content
DraconiticResearch
Search Sources API
201,642 studies31 sourcesUpdated 11 min ago
Peer-reviewedCC BY-NCBreast care (Basel, Switzerland)

CDK4/6 Inhibitors in the Treatment of Advanced ER/PR-Positive, HER2-Negative Breast Cancer: An Updated Single-Center Analysis of Real-World Data

  • Anna-Christina Rambow1
  • Tim Jannik Schröder1
  • Gudrun Wagenpfeil1
  • Peer Jansen1
  • Huy Duc Le1
  • Christoph Rogmans1
  • Nils Tribian1
  • Nicolai Maass1
  • Marion van Mackelenbergh1
  1. 1Department of Gynecology and Obstetrics, University Medical Center Schleswig-Holstein (UKSH), ,
Read full textPDFCite

Related

  1. Efficacy of anti-PD-1/PD-L1 plus chemotherapy in treatment-naïve advanced HER2-negative gastric adenocarcinoma among different PD-L1 intervals: an updated meta-analysis and reconstructed individual patient-level data analysis
    Yu-Kun Chen, Wen-Wei Wu, Fan Chen +6
    BMC MedicinePeer-reviewedCC BY 4.0Full textOncologyPMC
  2. PD-1/PD-L1 inhibitors combined with chemotherapy or as monotherapy versus chemotherapy alone or observation in triple-negative breast cancer: a systematic review and updated meta-analysis incorporating long-term survival data
    Bing Guan, Yawen Chen, Rong Zhou +3
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textOncologyCrossrefEurope PMC
  3. Integration of Immune checkpoint inhibitors within the definitive radiotherapy-based treatment continuum for locally advanced mucosal head and neck squamous cell carcinoma: a scoping review protocol
    Ahmad Ameri, Shahrzad Ebrahimi, Mansour Bahardoust +4
    BMJ OpenPeer-reviewedLicence not statedGeneral medicineCrossref
  4. Lorlatinib in frontline treatment of advanced ALK-positive non-small cell lung cancer: a highly efficient new standard of care but still challenging to manage
    Mylène Wespiser, Aurélie Swalduz, Maurice Pérol
    Translational Lung Cancer ResearchPeer-reviewedCC BY-NC-NDGeneral biologyOncologyHAL
  5. Sacituzumab govitecan plus pembrolizumab for advanced triple-negative breast cancer with PD-L1-positive: a cost-effectiveness analysis.
    Binliang Liu, Tao Wu, Fang Xu +7
    Health economics reviewPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMCDOAJ

Cite

BibTeXRIS
BibTeX
@article{rambow2026cdk46,
  title = {{CDK4/6 Inhibitors in the Treatment of Advanced ER/PR-Positive, HER2-Negative Breast Cancer: An Updated Single-Center Analysis of Real-World Data}},
  author = {Anna-Christina Rambow and Tim Jannik Schröder and Gudrun Wagenpfeil and Peer Jansen and Huy Duc Le and Christoph Rogmans and Nils Tribian and Nicolai Maass and Marion van Mackelenbergh},
  journal = {Breast care (Basel, Switzerland)},
  year = {2026},
  month = aug,
  url = {https://europepmc.org/article/PMC/PMC13690355},
  note = {CC BY-NC},
}
RIS
TY  - JOUR
TI  - CDK4/6 Inhibitors in the Treatment of Advanced ER/PR-Positive, HER2-Negative Breast Cancer: An Updated Single-Center Analysis of Real-World Data
AU  - Anna-Christina Rambow
AU  - Tim Jannik Schröder
AU  - Gudrun Wagenpfeil
AU  - Peer Jansen
AU  - Huy Duc Le
AU  - Christoph Rogmans
AU  - Nils Tribian
AU  - Nicolai Maass
AU  - Marion van Mackelenbergh
PY  - 2026
DA  - 2026/08/25
JO  - Breast care (Basel, Switzerland)
UR  - https://europepmc.org/article/PMC/PMC13690355
SN  - 1661-3791
SN  - 1661-3805
ER  -